MedTrace Logo

Adult Study / OROS Methylphenidate Hydrochloride (HCL) (OROS MPH) in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

NCT00937040 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 357

Last updated 2013-07-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the ADHD symptom response of adults with ADHD treated with OROS MPH to those treated with placebo.

Conditions

  • Attention Deficit Disorder With Hyperactivity

Interventions

DRUG

OROS MPH

Optimal Patient Dose (18 mg-72 mg) once daily for 6 weeks

DRUG

Placebo

Optimal Patient Dose (placebo to match 18 mg - 72 mg) once daily for 6 weeks

DRUG

OROS MPH Tablets

Optimal Patient Dose (18 mg-72 mg) once daily by mouth for 6 weeks

DRUG

Placebo Tablets

Optimal Patient Dose (placebo to match 18 mg - 72 mg) once daily by mouth for 6 weeks

Sponsors & Collaborators

  • Ortho-McNeil Janssen Scientific Affairs, LLC

    lead INDUSTRY

Principal Investigators

  • Ortho-McNeil Janssen Scientific Affairs, LLC Clinical Trial · Ortho-McNeil Janssen Scientific Affairs, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2010-02-28
Completion
2010-02-28

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00937040 on ClinicalTrials.gov